Algen Biotechnologies and AstraZeneca announced a drug discovery partnership valued at up to $555 million. The collaboration leverages Algen's AlgenBrain platform, which integrates single-cell CRISPR gene editing with artificial intelligence to identify gene regulation-disease associations in immunology. This alliance underscores a strategic push to accelerate discovery of novel immunology targets combining cutting-edge gene editing capabilities and AI-driven insights.